Form 4: Biodesix Executive O'Kane Converts Preferred Stock to Common Stock

Kieran O'Kane, Chief Commercial Officer of Biodesix Inc., converted Series A Non-Voting Convertible Preferred Stock into 13,080 shares of Common Stock on May 23, 2024, following stockholder approval.

Summary

• On May 23, 2024, Kieran O'Kane, the Chief Commercial Officer of Biodesix Inc., converted shares of Series A Non-Voting Convertible Preferred Stock into Common Stock.
• This conversion occurred following the approval by the Issuer's stockholders at the 2024 annual meeting held on May 21, 2024.
• Each share of Preferred Stock was automatically converted into 40 shares of Common Stock.
• O'Kane converted 327 shares of Preferred Stock into 13,080 shares of Common Stock.
• Following the transaction, O'Kane directly owns 88,604 shares of Common Stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (stock conversion) following shareholder approval, indicating a neutral to slightly positive sentiment as it simplifies the company's capital structure.

Positives

• The conversion of preferred stock to common stock simplifies the capital structure of Biodesix.
• The conversion reflects shareholder approval and alignment with the company's direction.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The conversion of preferred stock to common stock may have a minor dilutive effect on existing common shareholders.

Key Dates